Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1999 Mar;47(6):337–342. doi: 10.1007/s002620050539

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice

Laura J Esserman 1, Theresa Lopez 1, Ruben Montes 1, Laura N Bald 2, Brian M Fendly 2, Michael J Campbell 1
PMCID: PMC11037317  PMID: 10203064

Abstract

The HER2/neu oncogene product, p185HER2/ neu, is overexpressed on the surface of many human breast cancers. Strains of transgenic mice have been developed that express the rat neu oncogene in mammary epithelial cells and develop spontaneous mammary tumors that overexpress p185neu. This model provides an ideal system for testing interventions to prevent tumor development. In this study, we immunized neu-transgenic mice with a vaccine consisting of the extracellular domain of p185neu (NeuECD). Immunized mice developed Neu-specific humoral immune responses, as measured by circulating anti-Neu antibodies in their sera, and cellular immune responses, as measured by lymphocyte proliferation to NeuECD in vitro. In addition, the subsequent development of mammary tumors was significantly lower in immunized mice than in controls and vaccine treatment was associated with a significant increase in median survival.

Keywords: Key words Breast cancer vaccine, HER2/neu, Tumor immunotherapy, Transgenic mice

Footnotes

Received: 10 September 1998 / Accepted: 17 November 1998


Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES